<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ880311-0006 </DOCNO><HL> Business Brief: American Cyanamid Co. </HL><SO> </SO><CO> ACY APLY </CO><IN> TNM </IN><TEXT>   American Cyanamid Co. completed the purchase of more than 7% of a company that makes genetically engineered medical products, the companies said.    Cyanamid, Wayne, N.J., a marketer of chemicals and medical and consumer products, bought 380,000 shares of Applied Microbiology Inc., New York, and 190,000 warrants for an estimated $1.5 million. Cyanamid also has the option to buy at least 420,000 more shares and 210,000 warrants for a maximum of $1.5 million in the next 12 months.    Cyanamid agreed in May to acquire 15% of the company, plus the right to market its genetically engineered protein enzymes. Applied Microbiology said the enzymes can instantly kill a bacterium that causes bovine mastitis, a deadly disease in cows that is resistant to antibiotics.    In over-the-counter trading yesterday, Applied Microbiology was bid at $3.375 a share. </TEXT></DOC>